Publication shows benefit in patients with locally advanced or metastatic pancreatic cancer treated with nimotuzumab in combination with gemcitabine.
Oncoscience | November 17th, 2017
New publication shows benefit in patients with locally advanced or metastatic pancreatic cancer treated with nimotuzumab in combination with gemcitabine.
The findings from a double blinded randomized a Phase IIb/IIIa study combining nimotuzumab with gemcitabine in 192 patients with locally advanced or metastatic pancreatic cancer patients was recently published in the Annals of Oncology (Issue 10, 1 Oct 2017).
A total of 192 patients were randomly assigned to receive either nimotuzumab plus gemcitabine, or gemcitabine alone, with 1-year overall survival rates of 34% versus 19%, and median overall survival durations of 8.6 months versus 6.0 months, respectively (HR = 0.69; P = 0.03). The median progression free survival duration was 5.3 months in the experimental arm versus 3.5 months in the control arm (HR = 0.68; P = 0.02).
In a sub-group analysis, patients with pancreatic cancer and KRAS-wild-type disease who received nimotuzumab had significantly longer overall survival than those with pancreatic cancer KRAS-mutant disease (11.6 months versus 5.6 months; P = 0.03).
The randomized study showed that nimotuzumab in combination with gemcitabine is safe and well tolerated. The 1-year overall survival and progression free survival rates for the entire population were significantly improved. The study met its primary objectives.
To access the full publication please visit: https://academic.oup.com/annonc/article-abstract/28/10/2429/3926574?redirectedFrom=fulltext
Study ID: OSAG-101-PCS-07